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Abstract
Background: Vulvovaginal candidiasis (VVC) is an ordinary infection caused by Candida species. Meanwhile, a shift towards non-
albicans Candida (NAC) species has been detected in VVC patients.
Objectives: This study aimed at molecular identification of Candida isolates, causing VVC.
Methods: Vaginal secretion samples of 320 non-pregnant vaginitis patients at Shahid Akbar-Abadi Obstetrics and Gynecology Hos-
pital in Tehran (Iran) were collected. Samples were evaluated using mycological and molecular approaches. Vaginitis isolates were
analyzed with the PCR using NL1 and NL4 primers, and the D1/D2 region of the large-subunit rRNA gene was amplified and sequenced.
Results: In total, 100 Candida isolates were identified from VVC and recurrent vulvovaginal candidiasis (RVVC). Candida albicans was
the most frequent (51%), followed by C. glabrata (36%), C. krusei (Pichia kudriavzevii) (8%), and C. kefyr (Kluyveromyces marxianus) (5%).
51 and 49% of isolates had C. albicans and NAC, respectively.
Conclusions: Candida albicans and C. glabrata were the most common agents of vulvovaginal candidiasis. NAC spp. (49%) was found
as an important agent associated with VVC.
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1. Background
Vulvovaginal candidiasis (VVC) is an uncomfortable in-
fection that occures up to 75% of women at least once in
their life. Moreover, for a small percentage of women, it
occurs more than one episode (1, 2). Due to increased re-
sistance of Candida spp. to current antifungal drugs, the
challenge of recurrent vulvovaginal candidiasis (RVVC) is
on the rise (2, 3). Both pregnant and non-pregnant women
are at risk of vaginal colonization of Candida spp. (4, 5).
Candida albicans is the most important cause of VVC, while
non-albicans Candida (NAC) species is due to C. glabrata (5,
6). Also, NAC species including C. parapsilosis, C. tropicalis,
and C. krusei, are reported as causative agents of VVC, and
these species often no longer respond to antimycotic drugs
(1, 7).
Furthermore, the difficulty of definitive identifica-
tion of Candida species using conventional methods has
increased, particularly for unusual and closely related
species. Amplification of genomic DNA and sequencing of
the resulted amplicons is one of the most commonly used
molecular diagnostic techniques. Nucleotide sequence as-
sessment of the internal transcribed spacer section of the
rRNA gene (8) and the D1/D2 region of the large-subunit
rRNA gene are the most widely used techniques for defini-
tive identification of pathogenic fungal species (9, 10).
In the Candida complexes, such as the C. albicans com-
plex, amplification of the hyphal wall protein 1 (HWP1) gene
is the appropriate molecular approach for distinguishing
C. albicans, C. dubliniensis, and C. africana (11). Various Can-
dida spp. have different levels of susceptibility to antimy-
cotic drugs. Therefore, the exact identification of Candida
vaginal isolates is important for providing effective care.
2. Objectives
This study aimed at molecular identification of Can-
dida isolates, causing VVC using nucleotide sequences of
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the D1/D2 region of the large-subunit rRNA gene.
3. Methods
3.1. Patients and Collecting Isolates
This cross-sectional study was performed on 320 non-
pregnant vaginitis patients referred to Shahid Akbar-Abadi
Obstetrics and Gynecology Teaching Hospital in Tehran
(Iran) from 2016 - 2017. Besides, information on age,
occupation, medical history, symptoms, and recurrent
episodes (recurrent VVC was defined as ≥ 4 episodes
within a year) were also collected (12). Vaginal secretions
were collected from the posterior fornix with a sterile cot-
ton swab and put into 3 mL of sterile saline.
3.2. Exclusion Criteria
Infection with Mycoplasma spp., Trichomonas vaginalis,
Chlamydia, or any bacterial vaginosis or vulvar skin infec-
tion. History of using local or systemic antifungal com-
pounds during the past two weeks.
3.3. Yeast Identification
Microscopic assessment was used to identify yeast
forms or pseudomycelium. All specimens were cultured
on CHROMagar Candida (CHROMagar Candida, France) for
colony count and distinguishing concomitant of Candida
spp. infection. The identification was confirmed by germ
tube formation, chlamydospore production in cornmeal
agar (CMA) (Merck Germany) with 1% Tween 80, and cul-
tured on Sabouraud dextrose agar medium with chloram-
phenicol at 42°C.
3.4. Molecular Methods
For DNA extraction a single colony on CHROMagar
Candida was selected and subcultured on yeast extract
peptone dextrose (Merck Germany) (YEPD) agar at 37°C
for 24 - 48 h. Genomic DNA of yeast isolates was extracted
using the Qiagen DNA tissue kit (Germany) and deposited
at -20°C for until use. The universal primers NL1 (5′-GCA
TAT CAA TAA GCG GAG GAA AAG-3′) and NL4 (5′-GGT CCG
TGT TTC AAG ACG G-3′) were applied for amplification of
the D1/D2 region of large subunit ribosomal RNA (10) by
the subsequent program: 98°C (5 min), 35 cycles of 98°C
(30 s), annealing temperature 60°C (30 s), and 72°C (30 s)
and 72°C for a 5-minute final extension. The amplicons
were sequenced by Macrogen (Korea). Sequences were
evaluated by the reference nucleotide sequences retrieved
from the GenBank database with the BLAST sequence
search tool (http://www.ncbi.nlm.nih.gov/BLAST), and
results were deposited to GenBank. The PCR primers
CR-f (5′-GCTACCACTTCAGAATCATCATC-3′) and CR-r (5′-
GCACCTTCAGTCGTAGAGACG-3′) amplified the HWP1 gene
for identification C. albicans, C. africana, and C. dubliniensis
according to Romeo and Criseo PCR condition introducing
method (11). Candida albicans (ATCC 10231) was used as the
reference strain.
3.5. Phylogenetic Analysis
The sequencing results of the D1/D2 region was ex-
amined and compared with the reference nucleotide se-
quences of Candida spp. using the neighbor-joining
method by MEGA 7.
4. Results
In total, 320 non-pregnant vaginitis patients were in-
cluded in the present study. That 100 patients aged 18 -
56 years showed vaginal candidiasis. Most of them were
found in isolates of those aged 30 to 39 years old. 86% and
14% of cases were VVC and RVVC (Table 1). Most of the par-
ticipants were housewives (27%), followed by office workers
(25%), factory workers (22%), and self-employed (26%). None
of the participants had underlying diseases like diabetes,
urinary tract infections, immunocompromised diseases,
or any other chronic diseases. Primary identification of
the Candida spp. was conducted by germ tube test, CHRO-
Magar Candida, chlamydospore production, and cultured
at 42 ºC. C. albicans produced green-colored colonies on
CHROMagar Candida, chlamydospores on CMA medium,
and appeared germ tube in the test, as well.
Candida africana generated small green colonies
on CHROMagar Candida and did not generate chlamy-
dospores on CMA medium. Candida albicans strains grew
at 42°C, while the C. africana isolates did not. Candida
glabrata and C. kefyr (Kluyveromyces marxianus) produced
dark pink colonies with pale edges and light violet
colonies respectively. The clinical isolates with green-
colored colonies on CHROMagar Candida and reference
strain were analyzed with CR-f and CR-r specific primers
used to amplify the HWP1 gene, and the amplification
of the ~ 900-bp fragment confirmed C. albicans isolates
(Figure 1).
The PCR of the D1/D2 region of the large-subunit
rRNA gene with NL1 and NL4 primers amplified ~ 500 bp
fragment (Figure 2). The D1/D2 nucleotide sequences of
Candida spp. clinical strains were analyzed with refer-
ence nucleotide sequences retrieved from the GenBank
database using BLAST. The species of all clinical isolates
were identified. The D1/D2 sequences of Candida spp.
clinical isolates were deposited in GenBank under acces-
sion numbers KY548531-2, KY548534-KY548548, KY548550,
2 Jundishapur J Microbiol. 2020; 13(8):e106070.
Farahyar S et al.
Table 1. Distribution of Candida Isolates in Vaginal Discharge Samples According to Age Groups and Presence of VVC1 and RVVC2
Patient Characteristics
Candida Species
C. albicans C. glabrata C. krusei C. kefyr Totala
Age, y
> 20 3 1 0 0 4 (4)
20 - 29 17 13 3 3 36 (36)
30 - 39 22 14 4 0 40 (40)
40 - 49 8 6 1 2 17 (17)
50 - 59 1 2 0 0 3 (3)
Total 51 36 8 5 100
Vaginal candidiasis
VVC 44 32 6 4 86 (86)
RVVC 7 4 2 1 14 (14)
Total 51 36 8 5 100
Abbreviations: 1VVC, vulvovaginal candidiasis; 2RVVC, recurrent vulvovaginal candidiasis.
aValues are expressed as No. (%).
Figure 1. The clinical isolates were analyzed with CR-f and CR-r specific primers used
to amplify the HWP1 gene; lanes 1-3, C. albicans (~ 900 bp); lane 4, positive control C.
albicans (ATCC10231) ~ 900 bp. N, negative control; M, marker 100 bp.
MG025904-MG025928, MG025930-MG025933, MG966211-
MG966257, and MG967349-MG967353. C. albicans to be the
most strain (51%) in total of VVC patients, followed by C.
glabrata (36%), C. krusei (Pichia kudriavzevii) (8%), and C. ke-
fyr (K. marxianus) (5%). Among 14 RVVC cases, the most
common pathogen was C. albicans (50%), followed by C.
glabrata (28.6%), C. krusei (P. kudriavzevii) (14.3%), and C. kefyr
(K. marxianus) (7.1%) (Table 1). The nucleotide sequences of
the D1/D2 region were aligned for phylogenetic evaluation.
Candida albicans isolates showed similarity with KU729162
(C. albicans strain ATCC 28121), KY825125.1 (C. albicans iso-
late DA46), and MG859668.1 (C. albicans isolate HCM-NM58)
reference strains. Candida glabrata strains matched com-
pletely with MG859667.1 (C. glabrata isolate HCM-NM56)
and MG228366.1 (C. glabrata isolate DMic 154894) reference
strains in gene bank databases. Candida krusei (P. kudriavze-
vii) indicated 100% similarity to MG859665.1 (HN-NM19 iso-
late), C. kefyr (K. marxianus) displayed 100% identity with
MH595097.1 (UCDFST: 49-27 isolate) and CP023460 refer-
ence strain (Figure 3).
5. Discussion
In the present study, Candida spp. was the most impor-
tant agent of the fungal vaginitis. That is in line with the
findings of the previous studies that reported C. albicans
and C. glabrata as the most frequent pathogenic yeasts in
VVC patients (13-15). Several studies reported that the per-
centage of NAC isolates in vaginitis (5, 16) and also infec-
tions caused by unusual yeasts is on the rise (17). Tradi-
tional methods cause difficulties for definitive diagnosis of
the multiplicity of yeast species. Molecular approaches can
improve the differentiation of less common yeast isolates
and strongly similar yeast species such as those in Candida
complexes. DNA based approaches are most valuable for
Jundishapur J Microbiol. 2020; 13(8):e106070. 3
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Figure 2. The D1/D2 region of clinical isolates amplified with NL1 and NL4 primers, lanes 1-4: C. albicans; lanes 5-7: C. glabrata; lanes 8, 9: C. krusei; lanes 10, 11: C. kefyr. N, negative
control; M, marker 50 bp.
large epidemiological studies on unusual yeasts. Although
it rarely occurs, several studies have reported the Saccha-
romyces cerevisiae as the agent of genitourinary infection.
In the present study, we couldn’t find this yeast. However,
since it’s less susceptible to the currently available antifun-
gal drugs, S. cerevisiae is an important pathogenic yeast (18,
19).
In this study, routine mycological methods and DNA se-
quencing were used to identify yeast isolates. It’s proved
that sequencing the D1/D2 or ITS regions is an accurate
approach for definitive identification of pathogenic yeast
species, particularly the C. glabrata (17, 20), and the C. para-
psilosis complexes (21). The phylogenetic tree was built us-
ing the sequences of the D1/D2 region of different Candida
strains and indicated the creation of distinct branches for
Candida species. The phylogenetic analyses of the D1/D2 re-
gion showed that all C. albicans isolates had 100% homol-
ogy with KU729162 (C. albicans strain ATCC 28121), KY825125.1
(C. albicans isolate DA46), and MG859668.1 (C. albicans
isolate HCM-NM58) reference strains. C. glabrata strains
matched completely with MG859667.1 and MG228366.1 ref-
erence strains in gene bank databases. C. krusei (P. kudri-
avzevii) showed 100% homology with MG859665.1, and C.
kefyr (K. marxianus) showed 100% identity with MH595097.1
and CP023460 reference strains.
Hasanvand et al. (7) investigated C. albicans, C. glabrata,
C. tropicalis, and C. parapsilosis isolated from vaginitis pa-
tients and reported C. albicans as the main cause of vagi-
nal candidiasis. Several studies conducted in Iran and
other countries reported C. albicans as the predominant
pathogen in VVC (2-4, 6, 7, 12-16, 18, 22-24). Another study
has reported C. tropicalis as the main NAC species that cause
VVC (25), which is not consistent with the current study
that found C. glabrata as the first most frequently encoun-
tered NAC species.
Several studies mentioned C. glabrata as the important
NAC species in Candida vaginitis patients (5, 12, 14). The cur-
rent study revealed that C. krusei (P. kudriavzevii) and C. ke-
fyr (K. marxianus), as NAC species, are associated with vulvo-
vaginitis. Clinical isolates like C. krusei and C. glabrata were
resistant or showed low susceptibility to azole drugs, as re-
ported by other studies (5, 18). Candida glabrata is reported
as a common fungal pathogen in many countries and ap-
pears to be intrinsically resistant to fluconazole.
Another study reported C. lusitaniae isolates as the
second most common Candida species have also shown
susceptible to all tested antifungal drugs in VVC patients
(24), although this yeast was not reported in the current
study. Other NAC species such as C. tropicalis, C. parapsilo-
sis, Meyerozyma guilliermondii, C. dubliniensis, C. famata, C.
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Figure 3. The phylogenetic tree of Candida spp. was inferred based on the nucleotide sequences of the D1/D2 region. The evolutionary relationship of Candida spp created by
the neighbor-joining method, based on the nucleotide sequences of D1/D2 region retrieved from this study (KY548531-KY548532, KY548534-KY548537, MG025904-MG025905,
MG025907, MG025910, MG025913, MG025918-19, MG966212, MG966214-MG966221, MG966223- MG966225, MG966233-MG966252, MG966254-MG966257, MG967349-MG967353)
compared with reference sequences of C. albicans strains (KU729162, KY825125 and MG859668), C. glabrata strains (MG859667 and MG228366), C. krusei (Pichia. kudriavzevii;
MG859665), and C. kefyr (Kluyveromyces marxianus; CP023460) from GenBank. Bootstrap values achieved from 1000 replicates are indicated on branches in percentage. Evolu-
tionary evaluates were presented in MEGA7.
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africana, and C. orthopsilosis have frequently been reported
from VVC patients (7, 22, 24). In this study, C. albicans and C.
glabrata were the most important agents in VVC and RVVC.
Candida kefyr (K. marxianus) and C. krusei (P. kudriavze-
vii) were isolated from VVC and RVVC patients, as well.
In the present study VVC and RVVC patients were healthy
women without a history of exposure to known risk factors
such as diabetes, pregnancy, immunodeficiency disorders,
or any chronic disease. According to the clinical studies,
most of RVVC patients are healthy women, and multiple re-
curring infections are often idiopathic without known po-
tential risk factors (26). Numerous studies reported C. al-
bicans as the most prevalent species, even more than NAC
species, in vaginal candidiasis patients (2, 6, 7, 13, 15, 18,
22). Overall, C. albicans and non-albicans species had almost
similar rates of prevalence (51% versus 49% respectively).
Since NAC species often can be find in RVVC patients and do
not respond to standard antifungal therapies, their identi-
fication is of crucial importance. The results of this study
indicated that C. albicans and C. glabrata are still the princi-
pal pathogenic agents in recurrent and non-recurrent Can-
didal vaginitis.
5.1. Conclusions
Candida albicans and C. glabrata are the most impor-
tant Candida species isolated from VVC and RVVC, which
confirms the dramatic incidence of NAC species in VVC
patients. Accurate identification of Candida spp. is im-
portant for treatment administration because of some
strains revealed different levels of resistance to antimy-
cotic medicines.
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